Garth Powis

Q: What Schools Are Affiliated With Garth Powis

Garth Powis is affiliated with the following schools: Uppsala University, MD Anderson Cancer Center, University of Arizona, Sanford Burnham Prebys Medical Discovery Institute, Georgetown University, University of Glasgow

Garth Powis's AcademicInfluence.com Rankings

Garth Powis

Medical

#1360

World Rank

#1687

Historical Rank

Pharmacology

#105

World Rank

#134

Historical Rank

medical Degrees

Garth Powis

Biology

#5684

World Rank

#8221

Historical Rank

Neuroscience

#657

World Rank

#685

Historical Rank

Biochemistry

#693

World Rank

#793

Historical Rank

biology Degrees

Download Badge

Medical
Biology

Why Is Garth Powis Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Garth Powis's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. (1994) (720)
Thioredoxin reductase. (2000) (609)
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer (2015) (518)
Properties and biological activities of thioredoxins. (2001) (470)
The Absence of Mitochondrial Thioredoxin 2 Causes Massive Apoptosis, Exencephaly, and Early Embryonic Lethality in Homozygous Mice (2003) (438)
The role of the redox protein thioredoxin in cell growth and cancer. (2000) (438)
Free radicals in medicine. I. Chemical nature and biologic reactions. (1988) (423)
Passing the baton: the HIF switch. (2012) (416)
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. (2012) (413)
Free radical formation by antitumor quinones. (1989) (400)
The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. (2002) (359)
Free radicals in medicine. II. Involvement in human disease. (1988) (358)
Crystal structures of reduced, oxidized, and mutated human thioredoxins: evidence for a regulatory homodimer. (1996) (354)
HIF-1 regulation: not so easy come, easy go. (2008) (321)
Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. (1996) (319)
Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. (2004) (294)
Redox Potential of Human Thioredoxin 1 and Identification of a Second Dithiol/Disulfide Motif* (2003) (291)
Hypoxia inducible factor as a cancer drug target. (2003) (287)
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. (2009) (282)
The hypoxia-associated factor switches cells from HIF-1α- to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. (2011) (271)
Metabolism and reactions of quinoid anticancer agents. (1987) (269)
Redox signalling and the control of cell growth and death. (1995) (262)
Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. (1997) (261)
The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. (2003) (257)
Thioredoxin signaling as a target for cancer therapy. (2007) (256)
Cytosolic NAD(P)H:(Quinone‐acceptor)oxidoreductase in human normal and tumor tissue: Effects of cigarette smoking and alcohol (1990) (256)
Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents (2012) (255)
Glutathione S-transferase and glutathione peroxidase expression in normal and tumour human tissues. (1990) (245)
Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α (2004) (245)
Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues. (1992) (241)
Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α (2008) (233)
Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. (2003) (218)
3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth. (2000) (216)
Properties and biological activities of thioredoxins. (2001) (209)
Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. (2003) (209)
Hypoxia inducible factor-1alpha as a cancer drug target. (2004) (196)
Cloning and sequencing of a human thioredoxin reductase (1995) (195)
Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. (2000) (192)
Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity. (2004) (183)
Stability of Phosphoprotein as a Biological Marker of Tumor Signaling (2005) (174)
Hypoxia-Associated Factor, a Novel E3-Ubiquitin Ligase, Binds and Ubiquitinates Hypoxia-Inducible Factor 1α, Leading to Its Oxygen-Independent Degradation (2008) (174)
Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy (2009) (174)
Transfection with human thioredoxin increases cell proliferation and a dominant-negative mutant thioredoxin reverses the transformed phenotype of human breast cancer cells. (1996) (168)
Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. (2001) (167)
Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer. (2013) (161)
Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism. (1995) (154)
The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts (2005) (154)
The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some human tumors. (1994) (150)
Relationship of the single-electron reduction potential of quinones to their reduction by flavoproteins. (1980) (149)
The Promise of Patient-Derived Xenografts: The Best Laid Plans of Mice and Men (2012) (145)
Redox signaling and the control of cell growth and death. (1997) (141)
Mechanisms of the regulation of thioredoxin reductase activity in cancer cells by the chemopreventive agent selenium. (1997) (140)
Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. (1994) (134)
Signal transduction during human natural killer cell activation: inositol phosphate generation and regulation by cyclic AMP. (1988) (134)
Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. (1998) (133)
Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. (2005) (133)
The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures (2007) (133)
Cyclodextrin-derived diorganyl tellurides as glutathione peroxidase mimics and inhibitors of thioredoxin reductase and cancer cell growth. (2004) (123)
In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. (1995) (122)
Effect of selenium on rat thioredoxin reductase activity: increase by supranutritional selenium and decrease by selenium deficiency. (1999) (122)
Site-directed mutagenesis of active site cysteines in human thioredoxin produces competitive inhibitors of human thioredoxin reductase and elimination of mitogenic properties of thioredoxin. (1994) (121)
Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide, and doxorubicin. (2001) (120)
Cloning, sequencing and functional expression of a novel human thioredoxin reductase (1999) (117)
Pulse radiolysis studies of antitumor quinones: radical lifetimes, reactivity with oxygen, and one-electron reduction potentials. (1981) (116)
Quinone-stimulated superoxide formation by subcellular fractions, isolated hepatocytes, and other cells. (1981) (113)
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. (2010) (112)
Catalase-overexpressing thymocytes are resistant to glucocorticoid-induced apoptosis and exhibit increased net tumor growth. (2001) (110)
Regulation of Human Thioredoxin Reductase Expression and Activity by 3′-Untranslated Region Selenocysteine Insertion Sequence and mRNA Instability Elements* (1999) (110)
Inhibition of growth factor-dependent inositol phosphate Ca2+ signaling by antitumor ether lipid analogues. (1990) (108)
Signalling targets for anticancer drug development. (1991) (107)
Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. (2004) (105)
Expression of glutathione S-transferases and cytochrome P450 in normal and tumor breast tissue. (1990) (103)
Thioredoxin redox control of cell growth and death and the effects of inhibitors. (1998) (101)
Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models (2016) (99)
In vivo therapeutic silencing of hypoxia-inducible factor 1 alpha (HIF-1α) using single-walled carbon nanotubes noncovalently coated with siRNA (2009) (92)
The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects (2009) (91)
Purification of human thioredoxin reductase: properties and characterization by absorption and circular dichroism spectroscopy. (1993) (90)
OSU-03012 Promotes Caspase-Independent but PERK-, Cathepsin B-, BID-, and AIF-Dependent Killing of Transformed Cells (2006) (86)
Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients (2004) (86)
Human thioredoxin homodimers: regulation by pH, role of aspartate 60, and crystal structure of the aspartate 60 --> asparagine mutant. (1997) (85)
Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents. (1997) (84)
AMPKα modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer. (2012) (83)
The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma. (2006) (82)
The thioredoxin/thioredoxin reductase redox system and control of cell growth. (1994) (82)
Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues. (2003) (81)
Phosphatidylinositol 3-Kinase Mediates Bronchioalveolar Stem Cell Expansion in Mouse Models of Oncogenic K-ras-Induced Lung Cancer (2008) (80)
Radiosensitization and Stromal Imaging Response Correlates for the HIF-1 Inhibitor PX-478 Given with or without Chemotherapy in Pancreatic Cancer (2010) (79)
HNF4α is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer (2014) (77)
HIF-1alpha and cancer therapy. (2010) (77)
Metabolism and action of anti-cancer drugs (1987) (76)
Preferential inhibition of the platelet-derived growth factor receptor tyrosine kinase by staurosporine. (1990) (76)
Cellular thioredoxin reductase activity is regulated by selenium. (1997) (74)
Selenium and the thioredoxin redox system: effects on cell growth and death. (1997) (72)
Discovery of a novel class of AKT pleckstrin homology domain inhibitors (2008) (72)
Efficient synthetic routes to fluorinated isosteres of inositol and their effects on cellular growth (1990) (71)
Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin. (2004) (70)
PATHOME: an algorithm for accurately detecting differentially expressed subpathways (2014) (68)
Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor (2010) (67)
Oxidative inactivation of thioredoxin as a cellular growth factor and protection by a Cys73-->Ser mutation. (1996) (66)
Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase (2006) (66)
DT-diaphorase: questionable role in mitomycin C resistance, but a target for novel bioreductive drugs? (1989) (65)
Protection against adriamycin-induced skin necrosis in the rat by dimethyl sulfoxide and alpha-tocopherol. (1981) (65)
FXR silencing in human colon cancer by DNA methylation and KRAS signaling. (2014) (64)
Novel Water-Soluble Diorganyl Tellurides with Thiol Peroxidase and Antioxidant Activity. (1999) (63)
Redox control of caspase-3 activity by thioredoxin and other reduced proteins. (2000) (63)
Synthesis of the first optically pure, fluorinated inositol 1,4,5-trisphosphate of myo-inositol stereochemistry and its effect on Ca2+ release in Swiss 3T3 cells (1990) (63)
Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells. (2004) (61)
The Toxicity of Anticancer Drugs (1991) (61)
Cryopreservation of rat and dog hepatocytes for studies of xenobiotic metabolism and activation. (1987) (61)
Thioredoxin reductase and cancer cell growth inhibition by organotellurium antioxidants (2003) (61)
Downregulation of the antioxidant defence during glucocorticoid-mediated apoptosis. (1995) (59)
Pharmacokinetics of anticancer agents in humans (1983) (58)
Nuclear Factor κB Transactivation Is Increased But Is Not Involved in the Proliferative Effects of Thioredoxin Overexpression in MCF-7 Breast Cancer Cells (1999) (58)
Water-soluble organotellurium compounds inhibit thioredoxin reductase and the growth of human cancer cells. (2000) (58)
Treatment with HIF-1&agr; Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice (2010) (58)
In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. (2004) (58)
Inhibition of cellular thioredoxin reductase by diaziquone and doxorubicin. Relationship to the inhibition of cell proliferation and decreased ribonucleotide reductase activity. (1992) (58)
The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging. (2005) (56)
ERK5 signalling rescues intestinal epithelial turnover and tumour cell proliferation upon ERK1/2 abrogation (2016) (56)
Decreased antioxidant defence and increased oxidant stress during dexamethasone-induced apoptosis: bcl-2 prevents the loss of antioxidant enzyme activity. (1996) (56)
Thioredoxin reductase and cancer cell growth inhibition by organotellurium compounds that could be selectively incorporated into tumor cells. (2003) (55)
Quinoneimines as substrates for quinone reductase (NAD(P)H: (quinone-acceptor)oxidoreductase) and the effect of dicumarol on their cytotoxicity. (1987) (55)
Molecular modeling studies of the Akt PH domain and its interaction with phosphoinositides. (2001) (54)
Mechanism-based inhibition of thioredoxin reductase by antitumor quinoid compounds. (1992) (53)
Thioredoxin reductase and cancer cell growth inhibition by organogold(III) compounds (2006) (53)
Natural product based inhibitors of the thioredoxin-thioredoxin reductase system. (2004) (52)
Metabolite changes in HT‐29 xenograft tumors following HIF‐1α inhibition with PX‐478 as studied by MR spectroscopy in vivo and ex vivo (2005) (51)
Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs. (1997) (51)
An increase in intracellular free Ca2+ associated with serum-free growth stimulation of Swiss 3T3 fibroblasts by epidermal growth factor in the presence of bradykinin. (1988) (51)
Inhibition of the signalling enzyme phosphatidylinositol-3-kinase by antitumor ether lipid analogues. (1993) (51)
A study of the interaction of tetracycline with human serum lipoproteins and albumin (1974) (50)
Definition of a Novel Feed-Forward Mechanism for Glycolysis-HIF1α Signaling in Hypoxic Tumors Highlights Aldolase A as a Therapeutic Target. (2016) (50)
Signalling pathways as target for anticancer drug development (1994) (49)
Identification of Thioredoxin-Interacting Protein 1 as a Hypoxia-Inducible Factor 1&agr;-Induced Gene in Pancreatic Cancer (2008) (49)
Development of experimental models for meningeal neoplasia using intrathecal injection of 9L gliosarcoma and Walker 256 carcinosarcoma in the rat. (1986) (49)
Metabolic conversion of indicine N-oxide to indicine in rabbits and humans. (1979) (48)
IL‐24 is expressed during wound repair and inhibits TGFα‐induced migration and proliferation of keratinocytes (2009) (48)
In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT. (2009) (48)
Inhibition of protein tyrosine phosphatase by the antitumor agent gallium nitrate. (1993) (47)
Activation and inactivation of cancer chemotherapeutic agents by rat hepatocytes cocultured with human tumor cell lines. (1984) (46)
The hypoxic inducible stress response as a target for cancer drug discovery. (2006) (45)
Binding of catecholamines to connective tissue and the effect upon the responses of blood vessels to noradrenaline and to nerve stimulation (1973) (44)
Effect of a single oral dose of methanol, ethanol and propan-2-ol on the hepatic microsomal metabolism of foreign compounds in the rat. (1975) (44)
The binding of catecholamines to human serum proteins. (1975) (44)
Foreign compound metabolism studies with human liver obtained as surgical waste. Relation to donor characteristics and effects of tissue storage. (1988) (43)
Calorimetric study of microsomal membrane. (1977) (43)
New inhibitors of the thioredoxin-thioredoxin reductase system based on a naphthoquinone spiroketal natural product lead. (2001) (43)
3-Deoxy-D-myo-inositol 1-phosphate, 1-phosphonate, and ether lipid analogues as inhibitors of phosphatidylinositol-3-kinase signaling and cancer cell growth. (1998) (43)
Toxicity and pharmacokinetics of a pyrrolizidine alkaloid, indicine N-oxide, in humans. (1979) (42)
Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase (2011) (41)
Metabolism and covalent binding of [14C]toluene by human and rat liver microsomal fractions and liver slices. (1990) (41)
Incomplete hydrolysis of the calcium indicator precursor fura-2 pentaacetoxymethyl ester (fura-2 AM) by cells. (1988) (41)
Disposition and metabolism of pentamethylmelamine and hexamethylmelamine in rabbits and humans. (1979) (41)
Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase (1999) (40)
Growth factor and oncogene signalling pathways as targets for rational anticancer drug development. (1991) (40)
An alternatively spliced form of NQO1 (DT-diaphorase) messenger RNA lacking the putative quinone substrate binding site is present in human normal and tumor tissues. (1995) (40)
Practicalities of Drugging the Phosphatidylinositol-3-Kinase/Akt Cell Survival Signaling Pathway (2006) (39)
Over-expression of DT-diaphorase in transfected NIH 3T3 cells does not lead to increased anticancer quinone drug sensitivity: a questionable role for the enzyme as a target for bioreductively activated anticancer drugs. (1995) (39)
Inhibitors of phosphatidylinositol-3-kinase in cancer therapy. (2010) (39)
Human thioredoxin reductase gene localization to chromosomal position 12q23-q24.1 and mRNA distribution in human tissue. (1996) (38)
The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression (2014) (38)
Syntheses and biological activities of a novel group of steroidal derived inhibitors for human Cdc25A protein phosphatase. (2001) (37)
Proceedings of the Oxygen Homeostasis/Hypoxia Meeting. (2004) (36)
Anticancer drugs : reactive metabolism and drug interactions (1994) (35)
Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling. (2017) (35)
Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma. (2015) (35)
Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man. (1983) (35)
Modeling of Patient-Derived Xenografts in Colorectal Cancer (2017) (34)
Comparative studies of the in vitro metabolism and covalent binding of 14C-benzene by liver slices and microsomal fraction of mouse, rat, and human. (1990) (34)
Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM. (2011) (33)
Development of liver microsomal oxidations in the chick. (1976) (33)
A redox-inactive thioredoxin reduces growth and enhances apoptosis in WEHI7.2 cells. (2000) (33)
HAF: The new player in oxygen-independent HIF-1α degradation (2009) (33)
Anthracycline-induced inhibition of a calcium action potential in differentiated murine neuroblastoma cells. (1986) (32)
Redox active disulfides: the thioredoxin system as a drug target. (1997) (32)
Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs. (1982) (32)
The effects of volatile anesthetics on Ca++ mobilization in rat hepatocytes. (1990) (32)
Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis. (1983) (31)
Amiodarone-mediated increase in intracellular free Ca2+ associated with cellular injury to human pulmonary artery endothelial cells. (1990) (31)
Inhibition of phospholipase D by agents that inhibit cell growth. (1993) (31)
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. (2009) (31)
Recent development of anticancer therapeutics targeting Akt. (2011) (31)
Anticancer drug pharmacodynamics (1985) (31)
The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling (2006) (30)
Enzymatic and non-enzymatic reduction of N-acetyl-p-benzoquinone imine and some properties of the N-acetyl-p-benzosemiquinone imine radical. (1984) (29)
A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer. (2015) (29)
A new HIF‐1α/RANTES‐driven pathway to hepatocellular carcinoma mediated by germline haploinsufficiency of SART1/HAF in mice (2016) (29)
Increased NAD(P)H:(quinone-acceptor)oxidoreductase activity is associated with density-dependent growth inhibition of normal but not transformed cells. (1993) (28)
Anticancer drugs acting against signaling pathways. (1995) (28)
The redox protein thioredoxin-1 regulates the constitutive and inducible expression of the estrogen metabolizing cytochromes P450 1B1 and 1A1 in MCF-7 human breast cancer cells. (2002) (28)
Some properties of a preparation of rat colon perfused in vitro through the vascular bed (1971) (27)
Peroxisome proliferator-activated receptor γ agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity (2009) (27)
Contribution of external and internal Ca2+ to changes in intracellular free Ca2+ produced by mitogens in Swiss 3T3 fibroblasts: the role of dihydropyridine sensitive Ca2+ channels. (1989) (27)
A multiwell assay for inhibitors of phosphatidylinositol-3-kinase and the identification of natural product inhibitors. (1994) (26)
Nitrofurantoin-stimulated oxidant production in pulmonary endothelial cells. (1985) (26)
HIF-1–Dependent Stromal Adaptation to Ischemia Mediates In Vivo Tumor Radiation Resistance (2011) (26)
Macrocyclic pyrrolizidine alkaloids from Senecio anonymus. Separation of a complex alkaloid extract using droplet counter-current chromatography. (1988) (26)
Structure-activity relationship of aza-steroids as PI-PLC inhibitors. (2001) (25)
D-3-Deoxy-3-substitutedmyo-inositol analogues as inhibitors of cell growth (1991) (25)
Inhibiting the Hypoxia Response for Cancer Therapy: The New Kid on the Block (2009) (25)
Fluorescent probes towards selective cathepsin B detection and visualization in cancer cells and patient samples† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c9sc00997c (2019) (25)
Development of sulfonamide AKT PH domain inhibitors. (2011) (24)
Human and dog, but not rat, isolated hepatocytes have decreased foreign compound-metabolizing activity compared to liver slices. (1989) (24)
Enhanced mobilization of intracellular Ca2+ induced by halothane in hepatocytes isolated from swine susceptible to malignant hyperthermia. (1991) (24)
Role of metabolism and oxidation-reduction cycling in the cytotoxicity of antitumor quinoneimines and quinonediimines. (1987) (24)
Active oxygen in liver microsomes: mechanism of epinephrine oxidation. (1979) (24)
Effect of acetone administered in vivo upon hepatic microsomal drug metabolizing activity in the rat. (1974) (24)
Inositol Analogs as Potential Anticancer Therapeutics (1994) (23)
Pyridine nucleotide cofactor requirements of indicine N-oxide reduction by hepatic microsomal cytochrome P-450. (1980) (23)
Suramin blocks intracellular Ca2+ release and growth factor-induced increases in cytoplasmic free Ca2+ concentration. (1990) (23)
Inhibition of thioredoxin reductase (E.C. 1.6.4.5.) by antitumor quinones. (1990) (22)
Synthesis and biology of 1D-3-deoxyphosphatidylinositol: a putative antimetabolite of phosphatidylinositol-3-phosphate and an inhibitor of cancer cell colony formation. (1995) (22)
High-performance liquid chromatographic assay for the antitumor glycoside phyllanthoside and its stability in plasma of several species. (1985) (22)
The effects of exercise and adrenaline infusion upon the blood levels of propranolol and antipyrine in the horse. (1978) (22)
Determination of indicine N-oxide and indicine in plasma and urine by electron-capture gas-liquid chromatography. (1978) (22)
The Antitumor Agent Imexon Activates Antioxidant Gene Expression: Evidence for an Oxidative Stress Response (2007) (22)
Imexon Induces an Oxidative Endoplasmic Reticulum Stress Response in Pancreatic Cancer Cells (2012) (21)
HAF : the new player in oxygen-independent HIF-1alpha degradation. (2009) (21)
Increased thioredoxin-1 inhibits SSAT expression in MCF-7 human breast cancer cells. (2003) (21)
Sensitive high-performance liquid chromatographic assay for platinumin plasma ultrafiltrate (1984) (21)
A high-performance liquid chromatography assay for measuring integrated biphenyl metabolism by intact cells: its use with rat liver and human liver and kidney. (1987) (20)
Advances with phospholipid signalling as a target for anticancer drug development. (1995) (20)
The expression of the molecular chaperone calnexin is decreased in cancer cells grown as colonies compared to monolayer. (1997) (20)
Histamine-induced intracellular free Ca++, inositol phosphates and electrical changes in murine N1E-115 neuroblastoma cells. (1988) (20)
Hepatic microsomal metabolism of epinephrine and adrenochrome by superoxide-dependent and -independent pathways. (1979) (20)
Combined action of the dinuclear platinum compound BBR3610 with the PI3‐K inhibitor PX‐866 in glioblastoma (2011) (20)
The effect of inhibitors of alcohol metabolism upon the changes in the hepatic microsomal metabolism of foreign compounds produced by the acute administration of some alcohols to the rat. (1976) (19)
Reversible inhibition of human thioredoxin reductase activity by cytotoxic alkyl 2-imidazolyl disulfide analogues (2004) (19)
Stoichiometry of the mixed function oxidase. (1979) (19)
Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H:(quinone-acceptor)oxidoreductase (2004) (19)
Synthesis and Biological Activity of D-3-Deoxy-3-Fluorophosphatidylinositol—A New Direction in the Design of non-DNA Targeted Anticancer Agents† (1992) (19)
Phase I and pharmacokinetic studies of DON. (1981) (19)
Parallel syntheses of disulfide inhibitors of the thioredoxin redox system as potential antitumor agents. (1999) (19)
Transient increases of intracellular Ca2+ induced by volatile anesthetics in rat hepatocytes. (1990) (19)
Inhibiting intracellular signalling as a strategy for cancer chemoprevention. (1994) (19)
Iron-EDTA stimulated reduction of indicine N-oxide by the hepatic microsomal fraction, isolated hepatocytes, and the intact rat. (1982) (19)
The biological effects of isoform-specific PI3-kinase inhibition. (2010) (18)
Nuclear factor kappaB transactivation is increased but is not involved in the proliferative effects of thioredoxin overexpression in MCF-7 breast cancer cells. (1999) (18)
Synthesis and biological activity of prodrug inhibitors of the thioredoxin-thioredoxin reductase system. (2005) (18)
3-Deoxy-3-substituted-D-myo-inositol imidazolyl ether lipid phosphates and carbonate as inhibitors of the phosphatidylinositol 3-kinase pathway and cancer cell growth. (2001) (18)
Pilot study of PALA and 5-FU in patients with advanced cancer. (1982) (18)
Metabolism of the flame retardant plasticizer tris(2-chloroethyl)phosphate by human and rat liver preparations (1991) (18)
A multisample assay for inhibitors of phosphatidylinositol phospholipase C: identification of naturally occurring peptide inhibitors with antiproliferative activity. (1994) (17)
Anticancer drug testing in vitro: use of an activating system with the human tumor stem cell assay. (1981) (17)
3Beta-hydroxy-6-aza-cholestane and related analogues as phosphatidylinositol specific phospholipase C (PI-PLC) inhibitors with antitumor activity. (2000) (17)
Synthesis of D-3-deoxy-myo-inositol 1,4,5-trisphosphate and its effect on Ca2+ release in NIH 3T3 cells (1990) (17)
Doxorubicin blocks the increase in intracellular Ca++, part of a second messenger system in N1E-115 murine neuroblastoma cells. (1990) (16)
Inhibitors of phospholipid intracellular signaling as antiproliferative agents (1995) (16)
Doxorubicin-induced hair loss in the Angora rabbit: a study of treatments to protect against the hair loss (1987) (16)
Toxicity of intrathecally administered cytotoxic drugs and their antitumor activity against an intrathecal Walker 256 carcinosarcoma model for meningeal carcinomatosis in the rat. (1989) (16)
Systematic approach identifies RHOA as a potential biomarker therapeutic target for Asian gastric cancer (2016) (16)
Platelet-derived growth factor stimulates non-mitochondrial Ca2+ uptake and inhibits mitogen-induced Ca2+ signaling in Swiss 3T3 fibroblasts. (1990) (15)
Effect of washing the hepatic microsomal fraction in sucrose solutions and in sucrose solution containing EDTA upon the metabolism of foreign compounds. (1975) (15)
Novel quinone antiproliferative inhibitors of phosphatidylinositol-3-kinase. (1995) (15)
Superoxide dismutase is regulated by LAMMER kinase in Drosophila and human cells. (2009) (15)
N-Oxide reduction by hemoglobin, cytochrome C and ferrous ions. (1980) (15)
The use of human liver for foreign compound metabolism and toxicity studies. (1989) (15)
Absence of HIF1A leads to glycogen accumulation and an inflammatory response that enables pancreatic tumor growth. (2019) (15)
A versatile approach to PI(3,4)P2, PI(4,5)P2, and PI(3,4,5)P3 from L-(-)-Quebrachitol (2000) (15)
NADH synergism of microsomal aniline metabolism in the presence of enhancing agents. (1977) (14)
BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC). (2013) (14)
Signalling targets for the development of cancer drugs. (1994) (14)
Protection by alpha-tocopherol and dimethylsulfoxide (DMSO) against adriamycin induced skin ulcers in the rat. (1981) (14)
The Cell Membrane and Cell Signals as Targets in Cancer Chemotherapy AACR, EORTC, and BACR Special Conference in Cancer Research (1990) (14)
Disposition of tricyclic nucleoside-5'-monophosphate in blood and plasma of patients during phase I and II clinical trials. (1986) (14)
The effects of pargyline on overflow of transmitter and uptake of noradrenaline in the cat spleen (1973) (14)
Mechanisms of platelet-derived growth factor-induced arachidonic acid release in Swiss 3T3 fibroblasts: the role of a localized increase in free Ca2+ concentration beneath the plasma membrane and the activation of protein kinase C. (1993) (14)
Alternative splicing is associated with decreased expression of the redox proto-oncogene thioredoxin-1 in human cancers. (2001) (14)
Synthesis and biological activity of the D-3-deoxy-3-fluoro and D-3-chloro-3-deoxy analogues of phosphatidylinositol (1994) (14)
Potential use of human tissues for toxicity research and testing. (1989) (13)
Binding of copper and zinc by the antitumour agent L-alanosine. (1981) (13)
An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors. (2019) (13)
The accumulation and metabolism of (—)‐noradrenaline by cells in culture (1973) (13)
PI-3-Kinase inhibitors in colorectal cancer. (2011) (13)
Cigarette smoking is a determinant of DT-diaphorase gene expression in human non-small cell lung carcinoma. (1993) (13)
Dose-dependent pharmacokinetics and cancer chemotherapy (2004) (13)
Increased intracellular Ca2+ signaling caused by the antitumor agent helenalin and its analogues (1994) (13)
Anticancer drugs : antimetabolite metabolism and natural anticancer agents (1994) (12)
High molecular weight dextran sulfate inhibits intracellular Ca2+ release and decreases growth factor-induced increases in intracellular free Ca2+ in Swiss 3T3 fibroblasts. (1989) (12)
The effects of albumin upon the spectral changes and metabolism by the hepatic microsomal fraction. (1977) (12)
Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems (2016) (12)
Steroidal derived acids as inhibitors of human Cdc25A protein phosphatase. (2000) (12)
Effect of serum albumin upon the response of the rat isolated superfused anococcygeus muscle to catecholamines and to nerve stimulation (1974) (12)
Increased skin carcinogenesis in a keratinocyte directed thioredoxin-1 transgenic mouse. (2004) (12)
Studies of chemical toxicity to fresh and cryopreserved rat hepatocytes. (1989) (12)
The effect of pretreating rats with 3-methylcholanthrene upon the enhancement of microsomal aniline hydroxylation by acetone and other agents. (1975) (11)
KINETIC AND SPECTRAL EVIDENCE FOR MULTIPLE SPECIES OF CYTOCHROME P-450 IN LIVER MICROSOMES (1977) (11)
An uptake mechanism for L‐noradrenaline in the cat spleen, associated with the nerves but distinct from uptake1 (1974) (11)
Platelet-derived growth factor blocks the increase in intracellular free Ca2+ caused by calcium ionophores and a volatile anesthetic agent in Swiss 3T3 fibroblasts without altering toxicity. (1991) (11)
Pharmacokinetic studies of the herbicide and antitumor compound oryzalin in mice. (1997) (11)
Recent Advances in the Development of Anticancer Drugs that Act against Signalling Pathways (1994) (11)
A comment on the absence of calcium regulation of human thioredoxin reductase (1993) (11)
Tumor Growth Glucocorticoid-induced Apoptosis and Exhibit Increased Net Catalase-overexpressing Thymocytes Are Resistant to Updated Version (2001) (10)
Site-directed mutagenesis of Lys36 in human thioredoxin: the highly conserved residue affects reduction rates and growth stimulation but is not essential for the redox protein's biochemical or biological properties. (1995) (10)
Determination of pentamethylmelamine and hexamethylmelamine in plasma and urine by nitrogen-phosphorus gas-liquid chromatography. (1979) (10)
Synthesis and biological activity of 3-hydroxy(phosphono)methyl-bearing phosphatidylinositol ether lipid analogues (2002) (10)
Reversed-phase high-performance liquid chromatographic assay for the antineoplastic agent 9,10-anthracenedicarboxaldehyde bis(4,5-dihydro-1H-imidazol-2-yl hydrazone) dihydrochloride. (1981) (10)
Biochemical, structural, and biological properties of human thioredoxin active site peptides (1994) (10)
Enhanced formation of ethane and n-pentane by rat hepatocytes in the presence of dimethyl sulfoxide. (1986) (10)
Drugs active against growth factor and oncogene phosphatidylinositol signalling pathways. (1992) (10)
Synthesis of the First Optically Pure, Fluorinated Inositol 1,4,5‐ Trisphosphate of myo‐Inositol. Stereochemistry and Its Effect on Ca2+ Release in Swiss 3T3 Cells. (1991) (9)
Tumor Xenograft Response to Redox-Active Therapies Assessed by Magnetic Resonance Imaging Using a Thiol-Bearing DOTA Complex of Gadolinium. (2012) (9)
Inhibition of glycosylphosphatidylinositol (GPI) phospholipase D by suramin-like compounds. (1996) (9)
The effects of catecholamines upon the metabolism of foreign compounds and upon the distribution of perfusate in the isolated liver of the rat. (1974) (9)
Carbon tetrachloride-induced increase in the antitumor activity of cyclophosphamide in mice: A pharmacokinetic study (1984) (9)
Signalling pathways as targets for anticancer drug development. (1994) (9)
Determination of L-alanosine in plasma and urine by reversed-phase high-performance liquid chromatography of the Dns derivative. (1979) (9)
Effect of some anticancer drugs on the surface membrane electrical properties of differentiated murine neuroblastoma cells. (1987) (9)
Inhibitors of phosphatidylinositol signalling as antiproliferative agents (1994) (9)
Response of human multiple myeloma-derived cell lines to alkyl-lysophospholipid. (1996) (9)
Structural basis for the association of PLEKHA7 with membrane-embedded phosphatidylinositol lipids. (2021) (9)
Down regulation of the expression of the p110, p85 and p55 subunits of phosphatidylinositol 3-kinase during colon cancer cell anchorage-independent growth. (1999) (8)
Perfusion of rat’s liver with blood: transmitter overflows and gluconeogenesis (1970) (8)
Pharmacological Intervention with Signal Transduction (1994) (8)
Staurosporine inhibition of intracellular free Ca2+ transients in mitogen-stimulated Swiss 3T3 fibroblasts. (1990) (8)
Factors affecting the intracellular generation of free radicals from quinones. (1981) (8)
In vitro metabolism of [3H]2,6-dinitrotoluene by human and rat liver (1993) (8)
Inhibition of growth factor binding, Ca2+ signaling and cell growth by polysulfonated azo dyes related to the antitumor agent suramin (2004) (8)
Inhibition of intracellular Ca2+ signalling, cytotoxicity and antitumor activity of the herbicide oryzalin and its analogues (1997) (8)
Relationship of the reductive metabolism of indicine N-oxide to its antitumor activity. (1979) (8)
Metabolism of 2,6-dinitro[3-3H]toluene by human and rat liver microsomal and cytosolic fractions. (1992) (8)
Synthesis and Akt inhibitory properties of a 1d-3,4-dideoxyphosphatidylinositol ether lipid (2000) (8)
Clinical and pharmacologic evaluation of split-dose intermittent therapy with dianhydrogalactitol. (1982) (8)
Gas chromatographic assay for the new antitumor agent pyrazine-2-diazohydroxide (diazohydroxide) and its stability in buffer, blood and plasma. (1986) (7)
Effect of cyclophosphamide pretreatment on the short-term disposition and biliary excretion of adriamycin metabolites in rat (2004) (7)
Novel CDC25A phosphatase inhibitors from pyrolysis of 3-alpha-azido-B-homo-6-oxa-4-cholesten-7-one on silica gel. (1998) (7)
Increased toxicity of the antitumor drug cyclophosphamide in mice in the presence of the volatile anesthetic agent halothane (2004) (7)
New Inhibitors of the Thioredoxin—Thioredoxin Reductase System Based on a Naphthoquinone Spiroketal Natural Product Lead. (2010) (7)
Synthesis of D-3-deoxy-3-phosphonomethyl-myo-inositol and its dimethyl ester - compounds of use in studying the ptdins-3′-kinase signalling pathway (1993) (7)
Sensitive high-performance liquid chromatographic assay for platinum in plasma ultrafiltrate. (1984) (7)
Metabolism and disposition of 3-amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6, 8-pentaazaacenaphthylene in the rat. (1984) (7)
Synthesis of 1D-3-deoxy- and -2,3-dideoxyphosphatidylinositol (1997) (7)
Expedient synthetic routes to [3H]-D-3-azido-3-deoxy-myo-inositol and D-3-azido-3-deoxy-myo-inositol 2,4,5-trisphosphate (1992) (7)
In vitro cytotoxicity of pyrazine-2-diazohydroxide: specificity for hypoxic cells and effects of microsomal coincubation (1988) (6)
Metabolism of the flame retardant plasticizer tris(2-chloroethyl)phosphate by human and rat liver preparations. (1991) (6)
Structural basis for the association of PLEKHA7 with membrane-embedded phosphatidylinositol lipids (2020) (6)
Determination of 6-diazo-5-oxo-L-norleucine in plasma and urine by reversed-phase high-performance liquid chromatography of the dansyl derivative. (1980) (6)
High-performance liquid chromatographic assay of the antineoplastic agent tricyclic nucleoside 5'-phosphate and its disposition in rabbit. (1982) (6)
Semisynthetic pyrrolizidine alkaloid N-oxide antitumor agents. Esters of heliotridine. (1988) (6)
Hypoxia-associated factor expression in low-grade and anaplastic gliomas: a marker of poor outcome. (2016) (6)
The metabolism and binding of catecholamines by the hepatic microsomal mixed-function oxidase of the rat. (1976) (6)
Topical chemotherapy of intradermal Walker 256 carcinosarcoma with diaziquone and doxorubicin in the rat. (1985) (6)
Phase I and pharmacokinetic study of menogaril administered as a 72-hour continuous iv infusion (1987) (6)
DNA microarray reveals increased expression of thioredoxin peroxidase in thioredoxin-1 transfected cells and its functional consequences. (2001) (5)
Integrated Systems and Technologies AMPK a Modulation in Cancer Progression : Multilayer Integrative Analysis of the Whole Transcriptome in Asian Gastric Cancer (2012) (5)
Inhibition of growth factor binding and intracellular Ca2+ signalling by dextran sulfates of different sizes and degrees of sulfation (2004) (5)
A Fluorescence-Based High-Throughput Assay for the Identification of Anticancer Reagents Targeting Fructose-1,6-Bisphosphate Aldolase (2018) (5)
Disposition and metabolism of the antitumor agent pyrazine-2-diazohydroxide in mouse and beagle dog (1988) (5)
Oxidative metabolism of 14C-pyridine by human and rat tissue subcellular fractions. (1989) (5)
Pharmacokinetics and metabolism of the antitumor agent sulfamic acid 1,7-heptanediyl ester (sulfamic acid diester) in the mouse and beagle dog (1988) (5)
Dynamic Contrast-Enhanced and Diffusion MRI Show Rapid and Dramatic Changes in Tumor Microenvironment in Response to Inhibition of HIF-1 A Using PX-4781 (2005) (5)
Model systems for detecting the hepatic toxicity of pyrrolizidine alkaloids and pyrrolizidine alkaloid N-oxides. (1989) (5)
The binding of catecholamines to the serum proteins of the rat and the domestic fowl. (1975) (4)
Effects of advanced leukemia on hepatic drug-metabolizing activity in the mouse (2004) (4)
TACHYPHYLAXIS TO ETHACRYNIC ACID IN THE ISOLATED ATRIUM OF GUINEA‐PIG AND ITS RELATION TO NORADRENALINE STORES (1978) (4)
Inhibiting PI-3-K for glioma therapy (2009) (4)
Mice and Men The Promise of Patient-Derived Xenografts: The Best Laid Plans of (2012) (4)
Adenine and pyridine nucleotide concentrations and relationships to 2,6-dinitrotoluene metabolism in cultured rat liver slices. (1994) (4)
Metabolic stability of experimental chemotherapeutic agents in hepatocyte: tumor cell co-cultures (2004) (4)
Cancer Chemotherapy II: Laboratory to Clinic (1985) (4)
Cellular pharmacology ofd-3-azido-3-deoxy-myo-inositol, an inhibitor of phosphatidylinositol signaling having antiproliferative activity (2004) (4)
Effect of inhalation anesthetics on antipyrine pharmacokinetics of mice. (1987) (4)
A versatile approach to PI(3,4)P2, PI(4,5)P2, and PI(3,4,5)P3 from L-(-)-quebrachitol. (2000) (4)
Gas chromatographic assay for the new antitumor agent sulfamic acid diester (NSC 329680) and its stability in buffer, blood and plasma. (1988) (3)
Disposition and metabolism of the antitumor glycoside phyllanthoside in mouse and beagle dog (1986) (3)
From Bench to Bedside with Targeted Therapies (2008) (3)
Leukemogenic Nup98-homeobox fusion proteins are targeted to a novel nuclear compartment and cause mistargeting of endogenous Nup98 (2006) (3)
Improved synthesis of 17β-hydroxy-16α-iodo-wortmannin, 17β-hydroxy-16α-iodoPX866, and the [(131)I] analogue as useful PET tracers for PI3-kinase. (2013) (3)
Isolation, identification and biological activity of a phyllanthoside metabolite produced in vitro by mouse plasma (2004) (3)
The Effects of Catecholamines on Drug Metabolism in the Rat (1973) (3)
THE BINDING OF NORADRENALINE TO CONNECTIVE AND ELASTIC TISSUE (1976) (3)
The effects of sevoflurane on intracellular Ca2+ regulation in rat hepatocytes. (1993) (3)
The effect of adrenalectomy upon the absorption, distribution and metabolism of ethanol in the rat. (1977) (3)
An uptake process for L-noradrenaline resistant to desmethylimipramine (DMI) and 17 -estradiol in the cat spleen. (1973) (3)
Radiation Resistance in Cancer Therapy: Meeting Summary and Research Opportunities Report of an NCI Workshop held September 1–3, 2010 (2011) (3)
Cell signalling and cancer treatment (1998) (2)
Abstract A199: The plekstrin-homology-domain-containing protein PLEKHA7 is a novel target for selectively inhibiting mutant KRAS colon cancer cell proliferation. (2011) (2)
Phase I and pharmacokinetic study of menogaril administered as a 72-hour continuous i.v. infusion. (1987) (2)
Aberrant expression of NF-KB, NOS2 and tidoredoxin in the normal-appearing flat mucosa of patients with colonic neoplasia (2000) (2)
HUMAN THIOREDOXIN (OXIDIZED FORM) (1996) (2)
Occurs by a Novel Helper Mechanism (1995) (2)
Anticancer drugs and signalling targets : principles and examples (1995) (2)
Thioredoxin is a novel redox-dependent cytokine that promotes in vitro growth of normal and myelodysplastic bone marrow progenitors (2000) (2)
Preclinical pharmacologic studies of the new antitumor agent carmethizole (NSC-602668) in the mouse and beagle dog (2004) (2)
The metabolism and disposition of aniline in the isolated blood-perfused liver of the rat. (1975) (2)
Liver blood flow measurements with 85kripton clearance by portal venous and hepatic arterial routes of injection [proceedings]. (1977) (2)
Chapter 43 – From Bench to Bedside with Targeted Therapies (2008) (2)
Disposition and metabolism in mice of the potential antitumor and anti-human immunodeficiency virus-1 agent, 2-chloro-2′,3′-dideoxyadenosine (2004) (2)
Abstract 2157: Targeting the Maternal Embryonic Leucin zipper Kinase (MELK) in gastric cancers. (2013) (2)
Determination of pyrazoloimidazole in plasma and urine by gas-liquid chromatography using nitrogen-phosphorus detection. (1979) (2)
Induction of liver microsomal drug metabolism in newly-hatched chicks. (1973) (1)
PLEKHA7 signaling is necessary for the growth of mutant KRAS driven colorectal cancer. (2021) (1)
Abstract 2671: Targeting the KRAS signaling naocluster protein CNKSR1 provides antitumor activity against mutant KRAS xenografts (2014) (1)
Abstract 3632: Addition of the HIF-1α inhibitor PX-478 enhances the therapeutic efficacy of EGFR inhibitors in an orthotopic human lung adenocarcinoma model (2010) (1)
Radiation Resistance in Cancer Therapy: Meeting (2011) (1)
One-electron reduction potentials of chemotherapeutic quinones determined by pulse radiolysis (1981) (1)
Some characteristics of the uptake process in the isolated blood perfused cat spleen resistant to desmethylimipramine and 17- -oestradiol. (1973) (1)
Hedgehog signaling and desmoplasia are regulated by hypoxia in pancreatic cancer (2010) (1)
Abstract 2916: Targeting lysophospholipid metabolism inhibits pancreatic cancer cell proliferation under nutrient-limiting conditions (2018) (1)
Uptake of (L) noradrenaline in the isolated cat heart perfused with blood containing desmethylimipramine (DMI) and 17 β oestradiol (17βO) (1973) (1)
Effect of the monoamine oxidase inhibitor pargyline on the uptake of labelled noradrenaline by the cat's spleen. (1971) (1)
Targeting PI3K in Human Glioblastoma with PX-866, a small molecule PI3K inhibitor. (2007) (1)
Exosome-mediated MIR211 modulates tumor microenvironment via the DUSP6-ERK5 axis and contributes to BRAFV600E inhibitor resistance in melanoma (2019) (1)
Abstract 5534: Metformin increases AMPKα activity by inhibition of AMPKα and cell cycle proliferation in Asian gastric cancer. (2013) (1)
Active oxygen in hepatic microsomes (1976) (1)
Pancreas Cancer Molecular Targets for Therapy (2011) (1)
Potentiation of indicine n-oxide cytotoxicity by FE(III)complexes (1982) (1)
NADH-AND NADPH-DEPENDENT REDUCTION OF INDICINE N-OXIDE BY MICROSOMAL CYTOCHROME P-450 (1980) (1)
Synthesis and Biological Activity of the D-3-Deoxy-3-fluoro and D-3- Chloro-3-deoxy Analogues of Phosphatidylinositol. (1994) (1)
Pulse radiolysis measurement of one-electron reduction potential (E1 7) of adriamycin derivatives (1981) (1)
Abstract 955: Specific forms of mutant KRAS predict patient benefit from targeted therapy in the BATTLE-1 clinical trial in advanced non-small cell lung cancer (2011) (1)
Chapter 14 Free radicals in cell biology (1996) (1)
Plasma and tissue concentrations of hycanthone in the mouse determined by reversed-phase high-performance liquid chromatography. (1980) (1)
Achieving Personalized Cancer Medicine (2006) (1)
Abstract 3015: Selective inhibition of mutant KRAS cell and tumor growth by PHT-7.3, an inhibitor of the KRas signaling nanocluster protein Cnk1 (2017) (1)
Pharmacokinetic Basis for Drug Treatment (1984) (1)
Pharmacokinetic and pharmacodynamic studies of a novel antitumor wortmannin analogue inhibitor of phosphatidylinositol-3-kinase (2004) (1)
Drug clearance in the rabbit twenty-four hours after an intoxicating dose of ethanol [proceedings]. (1977) (1)
A Robust and Cost-Effective Luminescent-Based High-Throughput Assay for Fructose-1,6-Bisphosphate Aldolase A (2020) (1)
Abstract 513: Stromal desmoplasia is induced by a hypoxia and HIF-1α mediated increase in sonic hedgehog formation in pancreatic cancer (2011) (1)
The metabolism and binding of catecholamines by the hepatic microsomal fraction of the rat. (1976) (1)
The influence of halothane, enflurane and isoflurane on antipyrine pharmacokinetics in mice (1984) (1)
Abstract 2967: Pancreatic cancer cell growth requires lipids released by tumor-induced stroma autophagy (2017) (1)
PtdIns 3-kinase (2011) (1)
Abstract 2188: A high throughput RNAi screen for regulators of thioredoxin in pancreatic cancer cells identifies components of TGFβ-signaling as inducers of thioredoxin expression (2010) (0)
An isolated, innervated, blood perfused cat heart preparation (T) (1973) (0)
Abstract 1842: PHT-782 an inhibitor of the KRAS signaling nanocluster protein CNKSR1 blocks mutant KRAS signaling and cell growth but does not inhibit wild type KRAS cell growth (2012) (0)
Biological and Therapeutic Significance of Thioredoxin-1 (Trx-1) In Diffuse Large B-Cell Lymphomas (2010) (0)
Acquired mutations in MAPK signaling pathway following initial pharmacological response in BRAF-mutated metastatic colorectal cancer (mCRC). (2015) (0)
European School of Oncology Task Force Report. New approaches in cancer pharmacology: drug design and development (Part 2). (1994) (0)
Reduction of indicine N-oxide by microsomes, hepatocytes and rat liver in situ (1980) (0)
Proceedings: The effect of inhibitors of alcohol metabolism on the changes in the hepatic microsomal metabolism of foreign compounds produced by a single dose of ethanol in the rat. (1976) (0)
Metabolism of indicine N-oxide by the rabbit (1979) (0)
Cell signalling and cancer treatment. AACR special conference in cancer research in collaboration with the British Association for Cancer Research, the German Cancer Society (Section for Experimental Cancer Research), the Austrian Biochemical Society, and the Austrian Cancer Society. 23-28 February (1998) (0)
Overexpression in MCF-7 Breast Cancer Cells Involved in the Proliferative Effects of Thioredoxin B Transactivation Is Increased But Is Not κ Nuclear Factor (1999) (0)
Integrating whole transcriptome sequence data and public databases for analysis of somatic mutations in tumors (2011) (0)
3 – THE BINDING OF NORADRENALINE TO CONNECTIVE AND ELASTIC TISSUE (1977) (0)
Synthesis and Biological Activity of D‐3‐Deoxy‐3‐ fluorophosphatidylinositol ‐ A New Direction in the Design of Non‐DNA Targeted Anticancer Agents. (1993) (0)
Immunometabolism regulation by PSGL-1 signaling in tumor-specific CD8 T cells (2020) (0)
Abstract 970: Multi-layer and integrative analysis of the whole transcriptome in Asian gastric cancer: AMPKβ modulation in cancer progression (2012) (0)
Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems (2016) (0)
Correction: An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors. (2019) (0)
Abstract 4021: Genetic studies identify a map of redox signaling pathways inDrosophila (2010) (0)
Evaluation of platelet deposition at local thrombophlebitis, caused by intravenous infusion of anticancer drug (Bisantrene), with In-111-platelets in rabbits (1985) (0)
Cytotoxic Ether Lipid Analogues Selective Inhibition of Phosphatidylinositol Phospholipase C by Updated (2006) (0)
Erratum: The cell membrane and cell signals as targets in cancer chemotherapy (pp. 2203-2211, April 1, 1990) (1990) (0)
Synthesis of 1D-3-Deoxy- and -2,3-Dideoxyphosphatidylinositol. (1998) (0)
Rat spinal model for meningeal carcinomatosis and for assessing central nervous system (CNS) toxicity of anti-cancer drugs administered intrathecally (1985) (0)
methylation and KRAS signaling FXR silencing in human colon cancer by DNA (2016) (0)
Abstract PD4-6: Combined analysis of gene expression, DNA copy number and mutation profiling data to display biological process anomalies in individual cancers (2013) (0)
Proceedings: Uptake of (L)-noradrenaline in the isolated cat heart perfused with blood containing desmethylimipramine (DMI) and 17-beta-oestradiol (17beta0). (1973) (0)
Differential effect of extracellular calcium concentration on the cytotoxicity of chemotherapeutic agents to cultured Chinese hamster ovary [CHO] cells (1985) (0)
Ether Lipid Antitumor Agents Inhibit Phosphatidylinositol Phospholipase C (1993) (0)
In vitro metabolism of [(3)H]2,6-dinitrotoluene by human and rat liver. (1993) (0)
Radiation Resistance in Cancer Therapy: meeting summary and research opportunities. Report of an NCI Workshop held September 1-3, 2010. (2011) (0)
TheAntitumorAgent Imexon Activates Antioxidant Gene Expression : Evidence for an Oxidative Stress Response (2007) (0)
490 Potent and selective inhibitors of the KRAS-signaling nanocluster protein, CNKSR1, block oncogenic KRAS signaling and mut-KRAS cell growth (2014) (0)
Intrinsic Alteration of Differentiation and Glycolysis in T Lymphocytes Immediately After TCR Activation Through PSGL-1 Signaling (2019) (0)
Abstract 3836: A 3D high throughput RNA1 screen identifies the TLR4 kinase which alters spheroid architecture: a promising therapeutic strategy for pancreatic cancer. (2013) (0)
Activation and Inactivation of Cancer Chemotherapeutic Agents by Rat Hepatocytes Cocultured with Human Tumor Cell Lines1 (2006) (0)
Protection against adriamycin extravasation by α-tocopherol and dimethylsulfoxide (DMSO) (1981) (0)
Abstract 2303: The redox-active protein thioredoxin: A modulator of epithelial-mesenchymal transition (2010) (0)
Preclinical Therapeutic Sequencing using a Dual-Tracer Multi-Animal DCE-MRI Platform (2009) (0)
Novel Inhibitor Targeting ALDOA at Cysteine 289 and the Regulation of its C‐terminal Tail (2017) (0)
Primary Cancer Site (2011) (0)
HUMAN THIOREDOXIN (OXIDIZED WITH DIAMIDE) (1998) (0)
HUMAN THIOREDOXIN DOUBLE MUTANT WITH CYS 32 REPLACED BY SER AND CYS 35 REPLACED BY SER (1996) (0)
Abstract 3550: microRNA-211 promotes aggressive melanoma growthin vivoby epigenetic modification, and contributes to BRAFV600E inhibitor resistance via ERK5 signaling (2019) (0)
Immunopharmacogenetic factors affecting the sensitivity of inbred mouse strains to anticancer drugs (1983) (0)
Dispositionand Metabolismof Pentamethylmelamineand Hexamethylmelaminein Rabbitsand Humans' (2006) (0)
Abstract C131: ‘KRAS addiction’ an artifact of 2D culture? Inhibitors of the mut-KRAS NSCLC 3D growth (2015) (0)
siRNA silencing of mitochondrial thioredoxin-2 or peroxiredoxin-3 increases expression of glutaredoxin-2 and select members of the mitochondrial thioredoxin antioxidant pathway (2005) (0)
Triazine and Hydrazine Derivatives (1989) (0)
Abstract 3941: HAF promotes the switch from HIF-1α to HIF-2α signaling during chronic hypoxia and promotes stem cell characteristics (2012) (0)
Resistance and Sensitivity to Docetaxel Treatment of Breast Cancer Tissue in Mice Assessed by Analysis of Choline Compounds with HRMAS NMR Spectroscopy (2009) (0)
Oncogenic ras predicts lack of response to PX-866, an inhibitor of the phosphatidylinositol-3-kinase pathway in tumor xenograft models. (2007) (0)
Abstract 1781: Identification of focal adhesion and actin cytoskeleton regulation family genes as druggable target for gastric cancer (2014) (0)
Integrating whole transcriptome sequence data and public databases for analysis of somatic mutations in tumors (2011) (0)
Abstract 1975: PHuDock®, a computational discovery and development platform for novel PH domain-binding agents, identifies a novel antitumor AKT/PDPK1 inhibitor, PHT- 427 (2010) (0)
Doxorubicin (DOX)-induced electrophysiological changes in differentiated neuroblastoma cells (1985) (0)
Population Candidate Gene Association Study (2011) (0)
Abstract 4448: Identification of a small molecule inhibitor of aldolase A for the targeting of hypoxic cancer cells (2015) (0)
1164 – ETHACRYNIC ACID TACHYPH.YLAXIS IN ISOLATED GUINEA-PIG ATRIUM AND ITS REUTION TO NORADRENALINE STORES (1977) (0)
2528 – ACTIVE OXYGEN IN EPINEPHRINE OXIDATION TO ADRENOCHROME (1978) (0)
Efficient Synthetic Routes to Fluorinated Isosteres of Inositol and Their Effects on Cellular Growth. (1990) (0)
Distribution and metabolism of L-alanosine in man (1979) (0)
Abstract B139: Molecular pharmacology and antitumor activity of PHT‐427 a novel AKT/PDPK1 pleckstrin homology domain inhibitor (2009) (0)
Expression in Human Non-Small Cell Lung Carcinoma Cigarette Smoking Is a Determinant of DT-Diaphorase Gene Updated (2006) (0)
Sensitive reversed-phase high-performance liquid chromatographic assay for the antitumor agent benzisoquinolinedione (Nafidimide) employing direct on-column injection of plasma and urine, and its use for pharmacokinetic studies in a dog. (1985) (0)
Metabolism and Disposition of 3-Amino-1,5-dihydro-5-methyl-1-#-D- ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene in thÃ ̈Rat1 (2006) (0)
Abstract A25: Pancreatic cancer cells scavenge complex lipids from stroma in the hypoxic tumor microenvironment (2016) (0)
A344 HALOTHANE, ISOFLURANE AND Ca2+ TRANSIENTS IN CULTURED VASCULAR SMOOTH MUSCLE CELLS (1990) (0)
Effects of prior exposure to ketamine (K), halothane (H) and isoflurane (I) on the biliary excretion of tricyclic nucleoside (TCN) in the conscious rat (1984) (0)
The effect of a single dose of ethanol on the hepatic microsomal metabolism of foreign compounds in the rat. (1975) (0)
406 PHT-782 an Inhibitor of the KRAS Signaling Nanocluster Protein CNKSR1 Blocks Oncogenic KRAS Signaling (2012) (0)
Wortmannin analogs and methods for their use (2002) (0)
Synthesis of D‐3‐Deoxy‐myo‐inositol 1,4,5‐Triphosphate and Its Effect of Ca2+ Release in NIH 3T3 Cells. (1991) (0)
Growth Factor and Oncogene Signalling as a Target for Anticancer Drug Development (1994) (0)
Abstract PO014: PSGL-1 is an early T cell signaling regulator that drives immunometabolism and terminal differentiation in tumor-specific CD8 T cells (2021) (0)
Distribution and metabolism of hycanthone in mouse and in man (1980) (0)
Abstract 4481: Topical application of the dual PDPK1/AKT inhibitor PHT-427 inhibits signaling and growth of human breast cancer cutaneous metastases in mice (2011) (0)
Abstract A2-29: A PDK1 inhibitors that has antitumor activity in a vemurafenib resistant BRAF(V600E)::NRAS(G12V) melanoma PDX (2015) (0)
Proceedings: The isolated perfused rat liver in the study of the metabolism of foreign compounds. (1973) (0)
Abstract 3561: Silencing of farnesoid X receptor in human colon cancer by epigenetic mechanisms is associated with cancer progression. (2013) (0)
Personalized Medicine for Cancer (2008) (0)
434 POSTER Preclinical pharmacokinetic and comparative biodistribution studies of PX-866, a broad spectrum phosphatidylinositol-3-kinase (Pl-3K) Inhibitor, in F344 rats (2006) (0)
Abstract 2583: Refinement of inhibitors of the KRAS-signaling naocluster protein, CNKSR1, that block oncogenic KRAS signaling and growth (2015) (0)
Abstract A213: Topical PHT-427, a dual AKT/PDPK1 PH domain inhibitor, for treatment of primary and metastatic skin cancer. (2011) (0)
Signalling targets for the development of cancer drugs. (1994) (0)
Abstract 5505: A genome-wide siRNA screen for novel regulators of HIF-1α activity in normoxia and hypoxia (2010) (0)
Regulation of superoxide dismutase by Cdc-like-kinase (LAMMER kinase) in Drosophila Melanogaster and human tumor cells (2008) (0)
Abstract 3233: Modeling evolution of resistance in patient-derived xenografts: resistance to the BRAF inhibitor PLX4720. (2013) (0)
THE EFFECTS OF HALOTHANE (H), ENFLURANE (E), AND ISOFLURANE (I) ON Ca2+MOBILIZATION IN RAT HEPATOCYTES (1989) (0)
7 KRAS the Elephant in the Room of Cancer Therapy: New Approaches (2012) (0)
61 Patient-derived Metastatic Colorectal Cancer Mouse Tumorgrafts for Anticancer and Mechanism Studies (2012) (0)
HUMAN THIOREDOXIN (REDUCED FORM) (1996) (0)
HUMAN THIOREDOXIN (D60N MUTANT, REDUCED FORM) (1997) (0)
DNA Damage and Cellular Stress Responses Imexon Induces an Oxidative Endoplasmic Reticulum Stress Response in Pancreatic Cancer Cells (2012) (0)
Abstract B194: Enhanced antitumor activity of the HIF‐1 inhibitor PX‐478 combined with radiation and chemotherapy in pancreatic cancer (2009) (0)
Abstract 2076: Inhibiting glycolysis and HIF1α: a novel approach to cancer therapy. (2013) (0)
Abstract 3454: Establishing role of KRAS mutation on NSCLC radio-sensitivity (2012) (0)
Disposition and Metabolismof Pentamethylmelamine and Hexamethylmelamine in Rabbitsand Humans (1979) (0)
Abstract A10: Redox regulation of the Wnt/β-catenin pathway in colorectal cancer (2017) (0)
84 : Molecular-Genetic Imaging of In Vitro and In Vivo HIF-1 Signaling Response to Radiation (2006) (0)
Abstract 2428: Redox regulation of β-catenin in colorectal cancer (2018) (0)
Abstract 1559: Targeting the PH domain of Tiam-1 to inhibit breast cancer metastasis (2010) (0)
Wortmannin analog and procedures for their use (2002) (0)
Liver Disease and Anticancer Drug Treatment (1993) (0)
Abstract A197: Oncogenic KRAS is dependent on the scaffold protein CNKSR1 for cell growth and signaling. (2011) (0)
Article Commentary: Achieving Personalized Cancer Medicine: Trials and Tribulations (2006) (0)
HUMAN THIOREDOXIN MUTANT WITH CYS 73 REPLACED BY SER (REDUCED FORM) (1996) (0)
248 Antitumor activity, pharmacodynamics and toxicity of PX-866 a novel inhibitor of phosphoinositide-3-kinase (2004) (0)
Preclinical pharmacology studies of the antitumor glycoside phyllanthoside in mouse and beagle dog (1985) (0)
Synthesis and Akt Inhibitory Properties of a 1D‐3,4‐Dideoxyphosphatidylinositol Ether Lipid. (2000) (0)
Disposition of Tricyclic Nucleoside 5’-Phosphate (TCN-P, NSC 280594) in Man and Rat (1984) (0)
Radical formation during cellular and subcellualr metabolism of the chemotherapeutic agent AZQ (1980) (0)
Total Synthesis of 3‐Chloro‐3‐deoxy‐1‐O‐(1,2‐di‐O‐palmitoyl‐sn‐glycero‐ 3‐phospho)‐D‐myo‐inositol. A Potential Mechanistic Probe for Phosphoinositide Signal Transduction Pathways. (1994) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Garth Powis?

Garth Powis is affiliated with the following schools:

Garth Powis's Academic­Influence.com Rankings

Why Is Garth Powis Influential?

Garth Powis's Published Works

Published Works

What Schools Are Affiliated With Garth Powis?

Garth Powis's AcademicInfluence.com Rankings